Managing the patient with hard-to-control hypertension

American Family Physician

Volumn 57, Issue 5, 1998, Pages 1007-1014

  Oparil, Suzanne ^a   Calhoun, David A ^a  

^a UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDACTAZINE; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMILORIDE PLUS HYDROCHLOROTHIAZIDE; AMLODIPINE; AMLODIPINE PLUS BENAZEPRIL; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; ATENOLOL PLUS CHLORTALIDONE; BENAZEPRIL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; BISOPROLOL FUMARATE PLUS HYDROCHLOROTHIAZIDE; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL PLUS HYDROCHLOROTHIAZIDE; CLONIDINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; ENALAPRIL PLUS HYDROCHLOROTHIAZIDE; GUANETHIDINE; HYDRALAZINE; HYDROCHLOROTHIAZIDE PLUS LISINOPRIL; HYDROCHLOROTHIAZIDE PLUS LOSARTAN; HYDROCHLOROTHIAZIDE PLUS PROPRANOLOL; HYDROCHLOROTHIAZIDE PLUS TRIAMTERENE; LISINOPRIL; LOSARTAN; METHYLDOPA; PRAZOSIN; RESERPINE; TIMOLIDE; TIMOLOL; UNCLASSIFIED DRUG; VASODILATOR AGENT;

ALCOHOL CONSUMPTION; DRUG COST; HUMAN; HUMAN TISSUE; HYPERTENSION; OBESITY; PATIENT ATTITUDE; PATIENT COMPLIANCE; REVIEW; SLEEP APNEA SYNDROME; TREATMENT FAILURE;

ANTIHYPERTENSIVE AGENTS; DRUG COMBINATIONS; HUMANS; HYPERTENSION; PATIENT COMPLIANCE; PATIENT EDUCATION; RISK FACTORS; TEACHING MATERIALS;

EID: 0032031731     PISSN: 0002838X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (30)

1. The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1997;157:2413-46.
2. Greco BA, Breyer JA. The natural history of renal artery stenosis: who should be evaluated for suspected ischemic nephropathy? Semin Nephrol 1996;16:2-11.
3. Pickering TG, Mann SJ. Renovascular hypertension: medical evaluation and nonsurgical treatment. In: Laragh JH, Brenner BM, eds. Hypertension: pathophysiology, diagnosis, and management. 2d ed. New York: Raven, 1995:2039-54.
4. Manger WM, Gifford RW. Pheochromocytoma: a clinical overview. In: Laragh JH, Brenner BM, eds. Hypertension: pathophysiology, diagnosis, and management. 2d ed. New York: Raven, 1995:2225-44.
5. Bravo EL. Primary aldosteronism. Issues in diagnosis and management. Endocrinol Metab Clin North Am 1994;23:271-83.
6. The Fifth Report of the Joint National Committee on the Detection, Evaluation and Treatment of High Blood Pressure. Arch Intern Med 1993;153:154-83.
7. Setaro JF, Black HR. Refractory hypertension. N Engl J Med 1992;327:543-7.
8. Sica DA. Fixed-dose combination antihypertensive drugs. Do they have a role in rational therapy? Drugs 1994;48:16-24.
9. Materson BJ, Reda DJ, Cushman WC, Henderson WG. Results of combination anti-hypertensive therapy after failure of each of the components. Department of Veterans Affairs Cooperative Study Group on Anti-hypertensive Agents. J Hum Hypertens 1995;9:791-6.
10. Modan M, Almog S, Fuchs Z, Chetrit A, Lusky A, Halkin H. Obesity, glucose intolerance, hyperinsulinemia, and response to antihypertensive drugs. Hypertension 1991;17:565-73.
11. Puddey IB, Beilin U, Vandongen R. Regular alcohol use raises blood pressure in treated hypertensive subjects. A randomised controlled trial. Lancet 1987;1(8534):647-51.
12. Strollo PJ Jr, Rogers RM. Obstructive sleep apnea. N Engl J Med 1996;334:99-104.
13. Hla KM, Young TB, Bidwell T, Palta M, Skatrud JB, Dempsey J. Sleep apnea and hypertension. A population-based study. Ann Intern Med 1994;120:382-8.
14. Fletcher EC. The relationship between systemic hypertension and obstructive sleep apnea: facts and theory. Am J Med 1995;98:118-28.
15. Ram CV, Garrett BN, Kaplan NM. Moderate sodium restriction and various diuretics in the treatment of hypertension. Arch Intern Med 1981;141:1015-9.
16. National High Blood Pressure Education Program Working Group report on hypertension and chronic renal failure. Arch Intern Med 1991;151:1280-7.
17. Sackett DL, Haynes RB, Gibson ES, Hackett BC, Taylor DW, Roberts RS, et al. Randomised clinical trial of strategies for improving medication compliance in primary hypertension. Lancet 1975;1(7918):1205-7.
18. Management of patient compliance in the treatment of hypertension. Report of the NHLBI Working Group. Hypertension 1982;4:415-23.
19. Miller NH, Hill M, Kottke T, Ockene IS. The multilevel compliance challenge: recommendations for a call to action. A statement for healthcare professionals. AHA special report. Circulation 1997;95:1085-90.
20. Pickering TG. Clinical applications of ambulatory blood pressure monitoring: the white coat syndrome. Clin Invest Med 1991;14:212-7.
21. Pickering TG, James GD, Boddie C, Harshfield GA, Blank S, Laragh JH. How common is white coat hypertension? JAMA 1988;259:225-8.
22. Lerman CE, Brody DS, Hui T, Lazaro C, Smith DG, Blum MJ. The white-coat hypertension response: prevalence and predictors. J Gen Intern Med 1989; 4:226-31.
23. Weber MA, Neutel JM, Smith DH, Graettinger WF. Diagnosis of mild hypertension by ambulatory blood pressure monitoring. Circulation 1994;90:2291-8.
24. Glen SK, Elliott HL, Curzio JL, Lees KR, Reid JL. White-coat hypertension as a cause of cardiovascular dysfunction. Lancet 1996;348:654-7.
25. Appel LJ, Stason WB. Ambulatory blood pressure monitoring and blood pressure self-measurement in the diagnosis and management of hypertension. Ann Intern Med 1993;118:867-82.
26. Taguchi JT, Suwangool P. "Pipe-stem" brachial arteries. A cause of pseudohypertension. JAMA 1974;228:733.
27. Wright JC, Looney SW. Prevalence of positive Osler's manoeuver in 3387 persons screened for the Systolic Hypertension in the Elderly Program (SHEP). J Hum Hypertens 1997;11:285-9.
28. Messerli FH, Ventura HO, Amodeo C. Osler's maneuver and pseudohypertension. N Engl J Med 1985;312:1548-51.
29. Zuschke CA, Pettyjohn FS. Pseudohypertension. South Med J 1995;88:1185-90.
30. Anzal M, Palmer AJ, Starr J, Bulpitt CJ. The prevalence of pseudohypertension in the elderly. J Hum Hypertens 1996;10:409-11.